Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.37 |
| ▸ | CHRNG | P07510 | 1/20 | 0.37 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CHRND | Q07001 | 1/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | CTSE | P14091 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3611973 | 0.72 | TAAR1 (0.67) | BACE1TAAR1CTSD | |
| SCHEMBL3611977 | 0.72 | TAAR1 (0.67) | BACE1TAAR1CTSD | |
| SCHEMBL730328 | 0.71 | BACE1 (0.40) | BACE1KCNH2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL24342639 | 0.66 | CA1 (0.48) | BACE1KCNH2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL5640458 | 0.64 | CA1 (0.42) | BACE1CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL20790324 | 0.63 | CHRNA1 (0.47) | CHRNA1CHRNGCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL119428 | 0.63 | CHRNA1 (0.50) | BACE1CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL5046292 | 0.61 | CHRNA1 (0.45) | CHRNA1CHRNGCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL730344 | 0.61 | LMNA (0.40) | CHRNA1CHRNGCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL10195094 | 0.61 | BACE1 (1.00) | BACE1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138176-B2 | Imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | HEROLD PETER | 2011-04-21 | — | — | US | disclosed |
| US-7879847-B2 | such as 4-(5,6-Dihydro-8H-imidazo[5,1-c][1,4]oxazin-5-yl)benzonitrile, having aldosterone synthase and/or 11- beta -hydroxylase inhibitory activity, used for the treatment of hypertension and Cushing's Syndrome | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| EP-2007770-B1 | IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-20090192144-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-2007770-A1 | IMIDAZO COMPOUNDS | Speedel Experimenta AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007116099-A1 | IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192144-A1 | Imidazo Compounds | REN, CYP11B2, CYP11B1 | BACE1 2045/4885KCNH2 718/4885CHRNA1 1108/4885 |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | REN, CYP11B2, CYP11B1 | BACE1 2097/4885KCNH2 642/4885CHRNA1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.